Small-cap biotech companies can deliver outsized returns over the long run if they develop breakthrough medicines that go on to generate massive sales. However, some of these smaller drugmakers aren't ...
Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...
Recursion announces clinical trial approvals for REC-3565 and REC-4539, targeting B-cell malignancies and small-cell lung cancer. Recursion announced that the UK Medicines and Healthcare Products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results